 Usefulness suppression chronic ventricular arrhythmias Sotalol unique beta-blocking drug significant class III antiarrhythmic activity efficacy safety doses sotalol mg/day doses randomized double-blind multicenter study patients chronic ventricular premature complexes VPCs frequencies equal Sotalol VPCs patients low high doses patients placebo sotalol vs placebo high vs low dose individual efficacy criterion equal VPC reduction low-dose high-dose sotalol placebo-treated patients sotalol vs placebo high vs low dose Repetitive beats placebo difference significant low-dose high-dose sotalol Sotalol heart rate PR JT intervals ejection fraction Proarrhythmia nonfatal sotalol placebo patients Nine therapy adverse effects low dose high dose summary efficacious antiarrhythmic drug VPC suppression doses less effective